Owlstone Medical's Phase 2 clinical trial will assess the test's diagnostic performance and enable its optimization through testing protocol refinement.
Transcatheter structural heart therapies stand to replace their open-heart counterparts thanks to technological innovations and expanded patient access.
Blood-based liquid biopsy test analyzes DNA methylation pattern of cell-free DNA (cfDNA), indicating presence of hepatocellular carcinoma as early as Stage I.
Auris' robotic platform is currently used in bronchoscopic diagnostic and therapeutic procedures; J&J hopes to expand to other interventional applications.